Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIR-5818
- Development stage
- Phase 2
- Lead developer
- Vir Biotechnology
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
VIR-5818 is a bi-specific monoclonal antibody developed by Vir Biotechnology for the treatment of HER2-expressing solid tumors, including metastatic breast cancer and colorectal cancer. It is based on the XPAT (XTENylated Protease-Activated T Cell Engager) platform and functions as a protease-activated prodrug T-cell engager (TCE). The molecule comprises an XTEN polypeptide fused to single-chain variable fragments (scFv) targeting both HER2 and CD3, enabling selective activation of T cells in the tumor microenvironment. This dual-masked design aims to improve tolerability by limiting systemic immune activation while enhancing anti-tumor efficacy. VIR-5818 is administered intravenously and has shown promising early clinical activity with manageable safety in heavily pretreated patients with HER2-positive cancers[1][2][7].
- Brand names
- HER2-XPATHER-2-XPATHER 2-XPAT
- Other names
- anti-HER2 CD3 XTEN protease-activated T-cell engageranti-HER-2 CD3 XTEN protease-activated T-cell engageranti-HER 2 CD3 XTEN protease-activated T-cell engagerHER2-XPATHER-2-XPATHER 2-XPAT
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on VIR-5818.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIR-5818.